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ABSTRACT
We performed a comparative study and evaluated cellu-
lar infiltrates and anti-inflammatory cytokine production at
different time-points after syngeneic or allogeneic skin
transplantation. We observed an early IL-10 production in
syngeneic grafts compared with allografts. This observa-
tion prompted us to investigate the role of IL-10 in isograft
acceptance. For this, we used IL-10 KO and WT mice to
perform syngeneic transplantation, where IL-10 was ab-
sent in the graft or in the recipient. The majority of synge-
neic grafts derived from IL-10 KO donors did not engraft
or was only partially accepted, whereas IL-10 KO mice
transplanted with skin fromWT donors accepted the
graft. We evaluated IL-10 producers in the transplanted
skin and observed that epithelial cells were the major
source. Taken together, our data show that production of
IL-10 by donor cells, but not by the recipient, is determi-
nant for graft acceptance and strongly suggest that pro-
duction of this cytokine by keratinocytes immediately
upon transplantation is necessary for isograft survival. J.
Leukoc. Biol. 91: 000–000; 2012.
Introduction
Inflammation is inherent in surgical trauma in organ or tissue
transplantation and may significantly contribute to graft rejec-
tion. In conditions where donor-recipient MHC antigens mis-
match, alloantigens play a significant role in immune-mediated
tissue destruction. Amplification of the inflammatory response
is, in this context, the result of activation of alloreactive T cells
and recruitment of primed T cells and leukocytes into the
graft [1, 2]. Studies by El-Sawy et al. [3] show that recipient’s
CD8CD62low alloreactive T cells migrate into cardiac allo-
grafts very early on and up-regulate the inflammatory response
by an IFN--mediated effect. In models of syngeneic cardiac
and skin transplantation, neutrophil infiltration peaks early
but subsequently decreases [3, 4]. Therefore, absence of allo-
reactivity in isografts favors the resolution of inflammation and
consequently, graft acceptance. This phenomenon requires
pro- and anti-inflammatory factors to be tightly orchestrated to
guarantee modulation of the inflammatory response.
IL-10 is a regulatory cytokine produced by various immune
cells, including DCs, macrophages, T and B lymphocytes, mast
cells, NK cells, neutrophils and eosinophils (reviewed in ref.
[5]), and other cell types, such as keratinocytes [6]. IL-10 sup-
presses the release of proinflammatory mediators by mono-
cytes/macrophages and inhibits CD4 T cell activation by
modulating the expression of MHC II and costimulatory mole-
cules on APCs or acting directly by inhibiting proliferation and
cytokine synthesis of these T cells (reviewed in ref. [7]). In
patients undergoing liver resection, a transient increase of
IL-10 was observed during surgery, suggesting a role for this
cytokine in modulation of the inflammatory response during
the operative period [8]. In mice, the effect of treatment with
IL-10 on allograft survival is as yet unclear: some reports sup-
port a role for IL-10 in allograft acceptance [9–12], whereas
other studies show no effect [13–16].
Herein, we report the observation of an early IL-10 production
in syngeneic transplants compared with allogeneic grafts in a
time-course study, which prompted us to investigate the role of
this cytokine in isograft acceptance. Our data show that IL-10 in
the donor but not in the recipient tissues is determinant and
strongly suggest that production of this cytokine by keratinocytes
immediately upon transplantation is necessary for isograft sur-
vival.
MATERIALS AND METHODS
Animals
Eight- to 10-week-old BALB/c (H-2d), NZW (H-2z), C57Bl/6 (H-2b), and
C57Bl/6 Il-10/ male mice were obtained from the animal facility of the
Biomedical Institute of the University of Sa˜o Paulo (Sa˜o Paulo, Brazil).
C57Bl/6 IL-10IRESeGFP (IL-10 eGFP) [17] male mice were obtained from
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the animal facility of Instituto Gulbenkian de Cieˆncia (Oeiras, Portugal).
All animals were maintained under specific pathogen-free conditions on
standard pellet food and with water ad libitum. Experiments were per-
formed following the guidelines for animal use, approved by the Ethics
Committee on Animal Experimentation.
Skin transplantation
Donor tail skin was grafted on the back of recipients. Skin was excised
from the donor tail, cut into pieces, 1 cm2 in size, and kept in PBS at room
temperature until use. Grafts were placed on a bed prepared by removing
an area on the back dermis of the recipient, sutured, and covered with
gauze. Lack of acceptance was scored when 80% of the donor skin area was
destroyed.
Recovery of graft cells
Grafts were removed from the recipients, cut in four equal pieces, and
placed in 0.5 mL DMEM (Gibco-BRL, Life Technologies, Grand Island, NY,
USA), supplemented with 5% FBS (Hyclone, Logan, UT, USA), 105 M
2-ME (Sigma-Aldrich, St. Louis, MO, USA), 2 mM L-glutamine, 0.1 mM
vitamins, 1 mM sodium pyruvate, 0.1 mM nonessential amino acids, and
100 g/ml gentamicin (all from Gibco-BRL) in a 48-well plate. After incu-
bation for 24 h, the emigrated cells were removed, washed, counted, and
phenotyped using fluorescent antibodies. Histological examination at each
time-point after cell emigration showed that most of inflammatory cells em-
igrated from the transplants. Supernatants were collected and stored at
70°C until use. For histological analysis, grafts were soaked in OCT
(Tissue-Tek, Sakura Finetek USA, Torrance, CA, USA), frozen in dry ice,
and stored at 80°C.
Cytokine measurement
IL-10 and TGF- were quantified in the supernatants by two-step sandwich
ELISA using commercial kits from R&D Systems (Minneapolis, MN, USA),
according to the manufacturer’s instructions.
Flow cytometry
Cells were incubated for 20 min on ice with Fc block (hamster anti-
mouse CD16/32, clone 24G2) and subsequently labeled with fluorescent
mAb against GR-1(PE), CD11b(FITC), CD3(FITC), CD4(Cy), CD8(PE),
or matched isotype controls for 30 min. All antibodies were from
PharMingen, Becton Dickinson (San Diego, CA, USA). Cells were
washed and analyzed in a FACSCalibur (CellQuest software) cell cytom-
eter (Becton Dickinson).
Histolological analysis of skin
Frozen skin was cut in 10 m-thick slices using a Leica 3050S cryostat
(Leica Microsystems, Germany). Sections were labeled directly with DAPI
(500 g/ml) and phalloidin-tetramethylrhodamine B isothiocyanate (5 g/
ml; both from Sigma-Aldrich) for 5 min at room temperature in a dark
chamber. After three washes in PBS, slides were mounted with Mowiol
mounting media (Sigma-Aldrich) and images acquired in a DMRA2 Leica
microscope (Leica Microsystems) using Metamorph software.
IL-10 treatment
Commencing on the day of transplantation, C57Bl/6 mice were injected
daily with 500 pg purified rIL-10 (COS cell supernatant) in PBS (100 l/
animal) at the transplant site for a total of 6 days. The control group re-
ceived PBS only.
Statistical analysis
Graft survival was compared between groups by log-rank sum test; unpaired
t tests or ANOVA with Tukey’s post-test were used. Analyses were per-
formed using Prism 4.0 software (GraphPad Software, La Jolla, CA, USA).
Data were considered significant at P  0.05.
RESULTS AND DISCUSSION
Kinetics of inflammatory cell infiltration and
anti-inflammatory cytokine production in syngeneic
and allogeneic grafts
We evaluated cell infiltration and cytokine production in allo-
geneic and syngeneic grafts at different time-points after trans-
plantation. BALB/c (H-2d) recipients were grafted with the
allogeneic tail skin from NZW (H-2z) or syngeneic BALB/c
(H-2d) donors and monitored for 45 days for graft survival.
Allogeneic grafts were rejected with a median survival time of
9 days in BALB/c recipients, whereas all syngeneic transplants
were accepted (data not shown). For the comparative study,
grafts were excised at different time-points and cultured in
complete medium for an additional 24 h. Emigrating cells
were collected and phenotyped for polymorphonuclear (PMN)
cells (GR1high CD11b) and macrophages (GR1low CD11b)
(Fig. 1A), and CD4 and CD8 T cells (Fig. 1B). In general,
the number of cells infiltrating the grafts was similar in alloge-
neic and syngeneic transplants during the first 72 h (Fig. 1A
and B). We observed increased infiltration of PMN cells,
mainly neutrophils (GR1high CD11b), macrophages (GR1low
CD11b), and CD4 and CD8 T cells in allografts compared
with isografts on Day 7 post-transplantation. The number of
macrophages and PMN cells decreased constantly after 72 h in
isografts. These results show that the magnitude of leukocyte
infiltration during the first 72 h is independent of MHC do-
nor-recipient combinations. Previous studies have reported
enhanced PMN cell infiltration in cardiac allografts compared
to isografts, with a pathologic effect driven by early IFN--pro-
ducing CD8 T cells infiltrating the graft [3]. In our study,
allogeneic and syngeneic skin grafts had high infiltration of
neutrophils, 24 h after transplantation, which decreased pro-
gressively in the syngeneic combination reaching baseline val-
ues. In allogeneic skin grafts, we observed two waves of neutro-
phil infiltration. The second peak coincided with enhanced
CD8 and CD4 T cell infiltration (Fig. 1B). In syngeneic
grafts, the number of neutrophils that infiltrated was very simi-
lar to values in allogeneic transplantation. This suggests that
the latter observation might be related to tissue injury rather
than constituting a specific immune response. Unpublished
data from our group showed that depletion of PMN cells with
anti-GR-1 antibodies before allogeneic transplantation inter-
fered with vascularization of the graft, leading to death by hyp-
oxia. This suggests that neutrophils that infiltrate allografts in
the initial phase are not deleterious to the transplant. Studies
in the literature strongly support the role of neutrophils in
mediating angiogenesis through expression of a wide variety of
proangiogenic factors by these cells [17]. Therefore, appar-
ently, the absence of infiltrating neutrophils in the initial
phase affects neovascularization and wound healing. Moreover,
continuing entry of PMN cells into the allograft, especially af-
ter 72 h, also suggests that these cells are being recruited as a
result of the inflammatory context, a consequence of the allo-
reactive response. Decrease of neutrophil infiltrates at this
time-point in syngeneic grafts is strongly suggested to be asso-
ciated with modulation of inflammation. In fact, levels of
IFN- in allografts at Day 7 post-transplantation (5200696.8
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pg/ml) revealed a 19-fold increase compared with the previ-
ous time-point (72 h: 267.4165.5 pg/ml). In syngeneic grafts,
cytokine levels were similar to allografts at 72 h (137.052.6
pg/ml), decreased to undetectable levels on Day 7 (33.38.8
pg/ml), and were significantly lower compared with allografts
(P0.0018).
Regarding anti-inflammatory cytokines (Fig. 1C), TGF- was
already detected in supernatants within 7 h after transplanta-
tion; except for this time-point, no differences were observed
comparing allografts and isografts. Interestingly, IL-10 peaked
earlier in syngeneic grafts (at 24 h) and was at a higher level
in comparison with allogeneic grafts. This prompted us to in-
vestigate the influence of IL-10 on the outcome of syngeneic
skin transplantation.
IL-10 production by epidermal cells
We investigated the source of IL-10 production in the skin.
For this, we used the IL-10 eGFP mouse, where the eGFP cod-
ing sequence was gene-targeted to the Il-10 locus just down-
stream of the translation stop [18]. C57Bl/6 mice were grafted
with IL-10 eGFP or WT tail skin for 24 h. The graft was then
excised from the recipient and cultured in complete medium
for an additional 24 h to remove most of the inflammatory
cell infiltrates. Frozen sections were stained with DAPI and
phalloidin-rhodamine for nuclei and actin detection, respec-
tively. We observed GFP-positive cells in the epidermal layer
and surrounding the hair follicles of IL-10 eGFP skin but not
in WT grafts (Fig. 2A); fluorescent cells colocalized with cyto-
skeleton (Fig. 2B) but not cell nuclei (Fig. 2C), suggesting that
IL-10 has been produced by these cells and could be detected
in the cytoplasm. As keratinocytes are the dominant cell type
of the epidermis [19], our data strongly suggest that these
cells constitute the major population that secretes IL-10 in the
skin. Keratinocytes activated by UV radiation have already
been shown to be involved in immune suppression via produc-
tion of IL-10 [6, 20–22]. It is possible that in our model, IL-10
is being produced within a few hours after transplantation.
This would be crucial to control PMN influx at earlier time-
points (72 h; Fig. 1A), macrophages, and CD4 and CD8 T
cells in a later phase (7 days; Fig. 1A and B). Moreover, mac-
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Figure 1. Kinetics of inflamma-
tory cell migration and cytokine
production after allogeneic or
syngeneic skin transplantation.
BALB/c mice were grafted with
NZW or syngeneic tail skin.
Grafts were excised from the
hosts at different time-points and
cultured in complete medium
for 24 h. Total cells were col-
lected, counted, and phenotyped
by flow cytometry. Cytokine con-
tent of supernatants was mea-
sured by ELISA. (A) Number of
GR-1high and GR-1neg-low CD11b
cells. (B) Number of CD3CD4
and CD3CD8 cells. (C) TGF-
and IL-10 quantification. Results
are expressed as mean  sem.
*P  0.05; **P  0.01; com-
pared with isograft within the
same time-point or where indi-
cated. Results are representative
of three independent experi-
ments.
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rophages and T cells infiltrating syngeneic grafts may also be
IL-10 producers contributing to graft acceptance.
Evaluation of the importance of IL-10 in syngeneic
graft acceptance
To evaluate if early IL-10 production could be involved in
modulation of the inflammatory response in syngeneic grafts,
we transplanted C57Bl/6 WT or C57Bl/6 Il-10/ (IL-10 KO)
tail skin onto IL-10 KO recipients; in a reciprocal set-up, skin
from KO mice was grafted into WT recipients (Fig. 3A and B).
Grafts from IL-10 KO mice showed a lack of acceptance by
60% of IL-10-competent hosts (KO3WT; n15), whereas in
controls, all grafts were accepted (WT3WT; n11). When skin
from WT mice was transplanted onto IL-10 KO recipients, 80%
of individuals accepted the graft (WT3KO; n13). The inci-
dence of graft acceptance in the total absence of IL-10
(KO3KO; n17) was very similar to that observed when only
recipients lacked IL-10 (KO3KO vs. KO3WT, P0.41;
KO3KO vs. WT3WT, P0.0004; KO3KO vs. WT3KO,
P0.004; WT3WT vs. WT3KO, P0.18; WT3WT vs.
KO3WT, P0.002; WT3KO vs. KO3WT, P0.02). To evalu-
ate if rejection was associated with an indirect effect as a result of
absence of IL-10 production by donor cells, we treated donor
IL-10 KO skin immediately after transplantation and for 6 consec-
utive days with mouse rIL-10. Results showed that treatment par-
tially restored graft survival in WT recipients, as measured by per-
centage of accepted skin area compared with PBS-treated mice
(Fig. 3C). Although IL-10 KO grafts were not accepted com-
pletely when transplanted into WT recipients, there was an in-
crease of skin area accepted compared with controls. IL-10 ap-
pears to be important in this phenomenon at the very initial
stages of the inflammatory process. Our observations are in accor-
dance with various in the literature, which suggests a tolerogenic
role for IL-10 before and during the first priming events in organ
transplantation (reviewed in ref. [23]).
Previous studies have shown accelerated wound closure in IL-
10/ mice and an enhanced number of macrophages in inflam-
matory infiltrates compared with IL-10-competent controls [24].
These data suggest that in the absence of IL-10, these infiltrating
macrophages release TGF-1, which mediates myofibroblast dif-
ferentiation and rapid wound contraction. In fetal wounds, IL-10
KO grafts showed enhanced inflammation and increased colla-
gen deposition compared with WT wounds, suggesting a role for
this cytokine in regulating matrix deposition, as well as the ex-
pression of proinflammatory cytokines [25].
Analysis of cellular infiltration in grafts from IL-10 KO mice
transplanted onto IL-10-competent recipients shows enhanced
numbers of PMN cells and a slight decrease in infiltration of
macrophages, 7 days after syngeneic transplantation compared
with WT grafts transplanted onto WT recipients (Fig. 3D). We
observed no difference in numbers of CD4 and CD8 T cell
infiltrates or IFN- levels among these groups (data not shown).
These results suggest that lack of acceptance of IL-10 KO grafts
by WT recipients is mostly probably dependent on innate im-
mune mechanisms rather than the adaptive compartment. Never-
theless, we do not exclude the possibility that CD4CD25 Tregs
could be impaired in IL-10 KO skin, although we have not deter-
mined the Treg/CD4 effector T cell ratio in the grafts. As in
IL-10 eGFP WT
IL-10 eGFP WT
A
B
C
D
Figure 2. Cells from the epidermis are the main IL-10 producers in
the skin. Tail skin from IL-10 eGFP or WT mice was transplanted onto
WT recipients for 24 h. Grafts were then removed from recipients,
cultured for an additional 24 h to remove inflammatory cells, frozen,
and sectioned. Sections were labeled with DAPI (blue) and phalloidin
rhodamin (red) to stain cell nuclei and actin, respectively. (A) GFP
cells can be seen in the epidermis, which also surrounds a hair follicle
(dotted lines), and colocalize with actin (B) and cell nuclei (C). (D)
Merged images are magnified. Scale bars: 60 m. Results are represen-
tative of a group of five transplanted mice.
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autoimmunity, the lack of isograft acceptance could rely on im-
paired modulation of responder T cells to self-antigens. The im-
plication of CD4 and recently, CD8 Treg subsets in suppress-
ing effector T cell responses has been very well documented in
several experimental models of autoimmunity (reviewed in ref.
[26]). Although the degree of Treg involvement in skin isograft
tolerance is not clear, Tregs in the human skin have been shown
to exhibit proliferative and suppressive properties and could reg-
ulate the response to autoantigens exposed during injury [27]. A
decreased percentage of these cells in the LNs was associated
with impaired skin isograft acceptance in mice selected for mini-
mal inflammatory response [4].
Our results strongly suggest an important role for IL-10 in syn-
geneic graft acceptance and that the relevant source of IL-10 is
donor epidermal cells. Although cells from the recipient migrate
into donor tissue early on, IL-10 production by these leukocytes
does not seem to be sufficient to control tissue destruction when
donor skin lacks this cytokine. Differently from our results and in
another setting, responder allogeneic T cells have been shown to
be the major source of IL-10 production when cultured with au-
tologous epidermal cells [28]. In this case, autologous keratino-
cytes were the potent inducers of suppression to alloreactivity by
generating IL-10-secreting T cells; the contribution of keratino-
cytes themselves was marginal. Allogeneic skin sheets containing
tiny pieces of autologous skin epidermis have been used success-
fully to treat patients with severe burns [29, 30]. This indirect
keratinocyte-derived effect does not explain our results on WT
isograft acceptance in IL-10 KO recipients. In this case, the in-
volvement of host-derived, IL-10-secreting responder T cells is
lacking as a result of IL-10 KO reinforcing the direct contribution
of keratinocyte-induced IL-10 production to isograft tolerance.
Our data do not support the use of systemic of IL-10 in pa-
tients undergoing autologous skin transplantation as a result of
the small contribution of systemic IL-10 to skin isograft tolerance.
Nevertheless, it would be interesting to evaluate IL-10 production
in the donor skin during the initial phase of transplant, and local
IL-10 administration could be considered. In line with this idea,
some animal studies and even a clinical trial involving local ad-
ministration with IL-10 have been conducted, such as in IBD,
where systemically administered IL-10 has limited distribution to
the colonic site of inflammation [31]. Oral administration of ge-
netically modified Lactococcus lactis, which secretes IL-10 directly
in the gut, has been shown to improve IBD in a mouse model
and was being tested recently in a phase I clinical trial [32, 33].
The mechanisms by which IL-10 exerts its healing effects in
our model will require further investigation.
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